Compare SRCE & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRCE | NKTR |
|---|---|---|
| Founded | 1863 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 1995 | 1996 |
| Metric | SRCE | NKTR |
|---|---|---|
| Price | $90.09 | $72.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $74.50 | ★ $146.67 |
| AVG Volume (30 Days) | 119.4K | ★ 725.0K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 19.59 | N/A |
| EPS | ★ 3.58 | N/A |
| Revenue | N/A | ★ $307,711,000.00 |
| Revenue This Year | $10.29 | N/A |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $25.37 | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $56.89 | $21.60 |
| 52 Week High | $91.46 | $109.00 |
| Indicator | SRCE | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 74.15 | 58.40 |
| Support Level | $65.26 | $64.28 |
| Resistance Level | $91.46 | $76.32 |
| Average True Range (ATR) | 1.81 | 3.21 |
| MACD | 0.36 | 0.21 |
| Stochastic Oscillator | 88.89 | 82.98 |
1st Source Corp provides specialized financing services for construction equipment, aircraft, and vehicle types through its Specialty Finance activities. The company offers commercial, small business, agricultural, and real estate loans, along with commercial leasing, treasury management, and payment services, including Fedwires, ACH, and merchant services. It also provides Renewable Energy Financing for commercial solar projects, a full range of consumer banking products, Trust and Wealth Advisory Services, and insurance products. The company operates in the commercial banking segment, which provides commercial and consumer banking services, trust and wealth advisory services, and insurance to individual and business clients across its markets.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.